An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Maraviroc (Primary) ; Ritonavir; Saquinavir
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Pfizer; ViiV Healthcare
- 18 Nov 2010 Additional lead trial centre 'ViiV Healthcare' identified as reported by ClinicalTrials.gov.
- 13 Jan 2010 Actual patient number (30) added as reported by ClinicalTrials.gov.
- 25 Dec 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.